Abstract
Practical considerations for the choice of poliomyelitis vaccine in the United States are discussed. Both killed and live poliovirus vaccines protect against paralysis. They provide equivalent duration of immunity in individuals, equivalent protection against spread of poliovirus in communities, and equally rapid protection during epidemic outbreaks of poliomyelitis. The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine. Risks and benefits of "spreading immunity" by person-to-person transmission of live vaccine viruses are presented. Suggestions for reducing the incidence of live virus vaccine-associated disease are discussed. The level of protection against poliomyelitis that has been achieved in the general population of the United States has resulted in the virtual eradication of disease due to wild polioviruses. Routine use of killed poliovirus vaccine may eradicate all domestically arising poliomyelitis, both vaccine-associated and wild poliovirus disease, and may eliminate poliovirus from the United States.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
